A carregar...
Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combi...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6499443/ https://ncbi.nlm.nih.gov/pubmed/31118772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S180724 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|